CRB decided to integrate the groups to further focus on end-to-end design and construction organization in order to expand project execution and improve its client and employee experience.
CRB, a US-based engineering, architecture, construction, and consulting solutions company, announced on March 9, 2021 that it will be integrating its design and construction groups.
According to a company press release, CRB decided to integrate the groups to further focus on end-to-end design and construction organization in order to expand project execution and improve its client and employee experience. Specifically, the integration will include:
“These changes build on the project delivery successes of our ONEsolution approach, which sees clients through from initial planning and design to construction and operational readiness,” said Ryan Schroeder, president of CRB, in the press release. “They also position CRB as a preeminent choice for clients at a time when global health threats, intense competition, and shifting consumer habits are threatening legacy project delivery models.”
“Our clients face pressure every day to deliver their products in the face of strict budget controls and increasingly stiff competition. The marketplace is changing, ‘warp speed’ is becoming a new norm, and we continuously see the undeniable advantage in projects where the owner, designer, and builder work aligned as partners,” Schroeder added in the press release. “For clients, we increase our ability to deliver remarkable project experiences when we can truly align ourselves as partners. For our people, these changes open new career opportunities that will allow us to attract and retain the best talent in the industry.”
Source: CRB
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.